Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults
British Journal of Clinical Pharmacology · 2026
DOI: 10.1002/bcp.70482 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Hechuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, Inc., La Jolla, California, USA. Hauptthemen laut MEDLINE: Carbamazepine, Cytochrome P-450 CYP3A Inducers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Inc., Arvinas Estrogen Receptor, Inc..
Abstract (Originalsprache)
Aim
To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader.
Methods
This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants. During Period 1, a single oral dose of vepdegestrant 200 mg was administered (Day 1). During Period 2, carbamazepine dosing was titrated from 200 mg orally once daily (Days 1–3) to twice (Days 4–7) and three times daily (Days 8–19); a single oral dose of vepdegestrant 200 mg was administered (Day 14). Blood samples for pharmacokinetics analysis were collected up to 144 h after dosing in both periods. Safety was monitored throughout the study.
Results
Twelve healthy male participants were enrolled and treated. Following administration of vepdegestrant with (test) and without (reference) carbamazepine, test/reference ratios (90% confidence intervals) of the adjusted geometric means for vepdegestrant area under the plasma concentration–time curve from time 0 to infinity and maximum plasma concentration were 64.1% (60.0% to 68.4%) and 80.2% (74.0% to 86.8%), respectively. Similar decreases in ARV‐473 (vepdegestrant epimer) exposure were observed. Two participants discontinued during Period 2 due to elevated liver enzymes and maculopapular rash (both unrelated to vepdegestrant; one participant each).
Conclusion
Coadministration of multiple doses of carbamazepine 200 mg, a strong CYP3A4 inducer, with a single dose of vepdegestrant 200 mg resulted in a modest (36%) decrease in plasma vepdegestrant exposure. A single dose of vepdegestrant 200 mg was well tolerated in healthy adult participants. Clinical trial registration : NCT06005688.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pfizer, Inc., La Jolla, California, USA.
- Pfizer, Inc., Groton, Connecticut, USA.
- Pfizer, Inc., Collegeville, Pennsylvania, USA.
- Pfizer Clinical Research Unit, Brussels, Belgium.
- Arvinas Operations, Inc., New Haven, Connecticut, USA.
ORCID-Profile: Hechuan Wang, Alexandre Stouffs, Weiwei Tan
Förderung
- Pfizer, Inc.
- Arvinas Estrogen Receptor, Inc.
Zitieren
APA
Wang, H., Winton, J. A., Matschke, K. T., Stouffs, A., Lee, K. C., Zhang, Y., Qiao, W., & Tan, W. (2026). Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70482
Vancouver
Wang H, Winton JA, Matschke KT, Stouffs A, Lee KC, Zhang Y, et al. Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70482
BibTeX
@article{Wang2026,
author = {Wang, Hechuan and Winton, Jennifer A and Matschke, Kyle T and Stouffs, Alexandre and Lee, Kimberly C and Zhang, Yuanyuan and Qiao, Wenlian and Tan, Weiwei},
title = {Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70482}
}
EUVIMED